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University of Liverpool, Liverpool, United KingdomAbstractHealthcare-related transmission of Crimean-Congo haemorrhagic
fever (CCHF) is a well-recognized hazard. We report a
multicentre retrospective cross-sectional study undertaken in
Turkey in 2014 in nine hospitals, regional reference centres for
CCHF, covering the years 2002 to 2014 inclusive. Data were
systematically extracted from charts of all personnel with a
reported health care injury/accident related to CCHF. Blood
samples were tested for CCHF IgM/IgG by enzyme-linked
immunosorbent assay and/or viral nucleic acid detection by PCR
after the injury. Fifty-one healthcare-related exposures were
identiﬁed. Twenty-ﬁve (49%) of 51 resulted in laboratory-
conﬁrmed infection, with a 16% (4/25) overall mortality. The
main route of exposure was needlestick injury in 32/51 (62.7%).
A potential beneﬁt of post-exposure prophylaxis with ribavirin
was identiﬁed.© 2016 The Authors. Published by Els
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E-mail: hakanomu@yahoo.comCrimean-Congo haemorrhagic fever (CCHF) is a potentially
fatal viral disease and a major emerging infectious disease threat
after the expanding distribution of its main vector, ticks of the
genus Hyalomma [1]. CCHF is geographically widespread across
Africa, Eastern Europe, Asia and the Middle East [2] and is
occasionally seen in travellers returning from endemic areas [3].
Healthcare personnel are at risk from occupational in-
fections during patient care; the ﬁrst such cases were described
in Pakistan and were later reported from many Eurasian
countries [4–9]. Isolated imported cases of CCHF or outbreaks
in countries lacking CCHF experience present particular
infection control challenges, increased risk to healthcare
workers (HCWs), and are associated with increased mortality
[6]. Critical care management, associated with invasive pro-
cedures and the potential for aerosolization in highly viraemic
patients, poses additional challenges [7]. The beneﬁt and evi-
dence for ribavirin or other post-exposure prophylaxis (PEP)
options are lacking [8].
We undertook a multicentre retrospective cross-sectional
study in 2014 in nine hospitals in Turkey covering the years
2002 to 2014 inclusive. These nine centres managed approxi-
mately 50% of conﬁrmed cases of CCHF in Turkey during the
study period, acting as tertiary centres for more severe and
complicated disease.
We collected background data on the demographics of each
hospital population and extracted demographic, epidemiologic
and clinical data from the medical records of all personnel with
a reported healthcare-related exposure related to CCHF.Clin Microbiol Infect 2016; 22: 387.e1–387.e4
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CCHF IgM/IgG by enzyme-linked immunosorbent assay and/or
viral nucleic acid detection by PCR in regional reference labo-
ratories. Cases without results were excluded from analysis.
The outcomes were classiﬁed using a strict case deﬁnition: all
conﬁrmed HCW cases had positive serology (IgM or IgG
seroconversion) and/or positive PCR results. Thirteen of the
cases identiﬁed have been reported in two previous publica-
tions [8,9]. Asymptomatic cases were conﬁrmed by CCHF IgG
seroconversion.
During the study period 9069 conﬁrmed cases were reported
nationally with a case-fatality rate of 4.5% [10], of which 4869
cases were admitted to the nine centres with a case-fatality rate
of 6.7%. Fifty-one healthcare-related exposures were identiﬁed
in the nine centres, with four deaths. They comprised 22
physician trainees (residents) (43.1%), 21 nurses (41.2%), two
physician specialists (5.4%), two medical students (5.4%), two
other ward-based staff and two laboratory technicians.
The main routes of exposure were needlestick injury (NSI)
in 32/51 (62.7%), deﬁned blood/bodily ﬂuid exposure to mu-
cous membranes (splash) in 12/51 (23.5%) and unidentiﬁed in 7/
51 (13.7%). The exposures all occurred from cases that were
subsequently conﬁrmed to be CCHF positive by PCR. At the
time of the exposure, the majority of source cases were already
known to have conﬁrmed CCHF (28/50). Ten of 50 were
suspected cases, and 12/50 had not had a diagnosis of CCHF
considered at the time of exposure. Related to the recipient’s
exposure event, 48% of the source CCHF cases died.
Overall, 25/51 (49%) had laboratory-conﬁrmed infection
(Fig. 1a). After NSI, 8/32 (25%) had laboratory-conﬁrmed
infection, 3/8 (37.5%) of whom also had clinical disease. After
splash exposure, 10/12 (83.3%) had laboratory-conﬁrmed
infection, 8/10 (80%) of whom also had clinical disease. Seven
cases in HCWs had no identiﬁed source of exposure. All of
them had laboratory-conﬁrmed infection and clinical signs of
CCHF infection; one died. The two infections that occurred in
laboratory staff were included in the unidentiﬁed exposure
group, although one may have occurred while taking blood
from a CCHF patient and the second while handling a blood
sample in the laboratory without wearing gloves.
post-exposure ribavirin prophylaxis (oral formulation) was
administered after 19/32 NSI exposures. There were no cases
of clinical disease or laboratory-conﬁrmed infection in this
group. Median duration of ribavirin PEP was 7 days (range,
1–10 days), but systematic data on timing or dosage were not
available. In the known exposure group that did not receive
post-exposure ribavirin prophylaxis, 18/25 (68%) had
laboratory-conﬁrmed infection (8/13 in the NSI group), and 11/
25 (44%) had clinical disease (Fig. 1b). In the group that received© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microb
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4ribavirin PEP, 31.6% of the source cases died, whilst in the group
that did not receive ribavirin PEP, 67.7% of the sources died.
Healthcare-related transmission of CCHF virus is dangerous,
with an estimated total of 90–95 exposures of staff in 9069
admissions (~1%) in 12 years. The risk of CCHF virus trans-
mission in our series is 25% after a NSI. The data showing
higher rates of conﬁrmed infection after splash exposure
probably reﬂect reporting bias, but they may be inﬂuenced by
the higher rate of ribavirin PEP utilized in NSI. Clinical illness
developed in 18/25 of conﬁrmed infections, with a 22.2%
mortality rate.
During the study period, an estimated minimum of
90,000–100,000 blood samples from CCHF patients were
analysed in routine laboratories in the nine centres. All centres
currently use modern closed or semi-closed multichannel lab-
oratory equipment, and our data suggest that there is little
hazard from processing haematology and biochemistry blood
samples while following routine diagnostic laboratory pro-
cedures and using standard precautions.
Ribavirin has broad-spectrum antiviral activity, and although
it is associated with a number of adverse effects, most are mild,
and all are reversible. It is recommended for use in Lassa fever
PEP [11]. Although to our knowledge this is the largest data set
reported, the methodology and numbers are too small to draw
clear conclusions on the effectiveness of ribavirin administered
for CCHF PEP. An underlying bias may have inﬂuenced cases
selected for ribavirin PEP, and it is not possible to adjust for
other factors that may have inﬂuenced the results. For example,
the case fatality rate of the source CCHF patients (causing the
exposure) was lower in the group that received ribavirin PEP
than in those that did not. Because of the lack of efﬁcacy of
studies to date [12], ribavirin is no longer routinely used in the
treatment of CCHF in Turkey. It is possible that it is effective
when there is a smaller inoculum, but it is ineffective in treating
the high virus loads of clinical disease. There is no clear
consensus on the ribavirin dosage for PEP, and its role can only
fully be answered by well-designed multicentre controlled
prospective studies.
Despite the potential availability of PEP for any viral hae-
morrhagic fever (VHF), the protection of all staff against
nosocomial exposure and infection is paramount. Lessons in
HCW protection can be learned from the ongoing Ebola virus
disease epidemic, particularly in the routine utilization of per-
sonal protective equipment. Ward-based staff undertaking
invasive procedures and dealing with CCHF patient contacts
are most at risk. This particularly includes trainees and students,
where there is high staff turnover. Advanced infection pre-
vention and control (IP&C) training focused on sharps safety
and personal protective equipment is vital for all clinical staff in
endemic areas, accompanied by wider education of all HCWs,iology and Infectious Diseases, CMI, 22, 387.e1–387.e4
.0/).
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FIG. 1. (a) Exposure and outcomes of 51 CCHF HCW exposures, related to mode of exposure and laboratory conﬁrmation. (b) Outcome of CCHF
HCW exposures stratiﬁed by administration of PEP. CCHF, Crimean-Congo haemorrhagic fever; HCW, healthcare worker; PEP, post-exposure
prophylaxis.
CMI Leblebicioglu et al. Crimean-Congo haemorrhagic fever 387.e3
© 2016 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases, CMI, 22, 387.e1–387.e4
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
387.e4 Clinical Microbiology and Infection, Volume 22 Number 4, April 2016 CMIbecause CCHF was not initially considered in 25% of exposure
cases. Every CCHF exposure, infection or death of a HCW
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